How Much is ResMed (ASX:RMD) Worth by Market Capitalisation?

Sonal Goyal

13 July 2026 12:20 AM AEST

How Much is ResMed (ASX:RMD) Worth by Market Capitalisation?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

ResMed shares declined 4.861% during the latest ASX trading session.
The stock traded between AUD 28.210 and AUD 29.080 intraday.
ResMed's market capitalisation stood at AUD 43.31 billion.

ResMed Inc (ASX:RMD) traded lower during the latest session, with the stock declining 4.861% to AUD 28.570. The fall followed the previous closing price of AUD 30.030.

During the trading session, the shares moved within an intraday range of AUD 28.210 to AUD 29.080. The bid and offer were quoted at AUD 28.520 and AUD 29.000, respectively, while the company remained listed as currently trading.

Trading Volume Exceeds Daily Average

Market participation increased during the latest session, with 2,694,062 shares changing hands. This exceeded the stock's average daily trading volume of 1,609,688 shares.

Higher trading volume reflects elevated market activity during the session but does not, by itself, indicate future share price direction.

Market Capitalisation and Share Information

ResMed has a market capitalisation of AUD 43.31 billion and is classified under the Health Care Equipment & Services industry group on the Australian Securities Exchange.

The company has been listed on the ASX since 25 November 1999. It has 1,442,395,630 CDI 10:1 Foreign Exempt NYSE securities on issue. Its ISIN is AU000000RMD6, while its foreign exempt status is listed as "Yes."

Stock Trades Within Its 52-Week Range

According to the latest available market data, ResMed shares have traded between AUD 25.500 and AUD 45.250 over the past 52 weeks.

At the latest traded price of AUD 28.570, the stock remains above its 52-week low and below its 52-week high. The 52-week range provides historical context for the stock's price performance over the past year.

Valuation Snapshot

ResMed is currently trading with a reported price-to-earnings (P/E) ratio of 19.65. The P/E ratio compares the company's share price with its earnings per share and is one of several valuation measures monitored by market participants.

Investors commonly assess trading volume, market capitalisation, valuation metrics and company disclosures alongside broader healthcare sector developments when evaluating listed companies.

Key Risks

Healthcare sector sentiment may influence share price movements.
Higher trading activity can increase short-term volatility.
Currency movements may affect foreign exempt securities.
Market conditions may impact valuation multiples.

Summary

ResMed Inc (ASX:RMD) declined 4.861% during the latest trading session to AUD 28.570 from the previous close of AUD 30.030. The stock traded between AUD 28.210 and AUD 29.080, while trading volume reached 2.69 million shares, exceeding the average daily volume. The company has a market capitalisation of AUD 43.31 billion and a reported P/E ratio of 19.65.

FAQs

Q: What was ResMed's latest share price?

A:ResMed shares traded at AUD 28.570, down 4.861% during the latest ASX trading session.

Q: How many ResMed shares were traded today?

A:Approximately 2.69 million ResMed shares changed hands, exceeding the stock's average daily trading volume.

Q: What is ResMed's market capitalisation?

A:ResMed had a market capitalisation of approximately AUD 43.31 billion based on the latest available market data.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.